NYSE:MRX

Medicis Pharmaceutical (MRX) Stock Price, News & Analysis

Notice: This company recently went public with an IPO on Thursday, April 25th 2024. They issued 15,384,615 shares at $18.00-$21.00 per share. We will continue to update data for MRX as it becomes available.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MRX stock logo

About Medicis Pharmaceutical Stock (NYSE:MRX)

Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

MRX Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
TLPPF Telix Pharmaceuticals Limited
AcelRx Pharmaceuticals Inc ACRX
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Ananda Developments Plc - Result of General Meeting
Boston Pharmaceuticals News
Medicis to Acquire Inamed
Medicis Stock Hits New 52-Week High (MRX)
Medicis Pharmaceutical Corp (MRX)
See More Headlines
Receive MRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Robert Roswell Chai-Onn (Age 44)
    Executive Vice President, General Counsel, Secretary, Director
  • Howard Bradley Schiller (Age 53)
    Officer, Director
  • Ryan Weldon
    Officer, Director

MRX Stock Analysis - Frequently Asked Questions

When did Medicis Pharmaceutical IPO?

Medicis Pharmaceutical (MRX) raised $300 million in an IPO on Thursday, April 25th 2024. The company issued 15,384,615 shares at $18.00-$21.00 per share.

This page (NYSE:MRX) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners